相关实验视频

Updated: Feb 24, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

通过分子打印的纳米颗粒提高免疫疗法效率,共同准差异化-73的集群和编程死亡-联体1的编程死亡

Yanjie Han¹, Haohao Song¹, Zikuan Gu¹

¹State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, 163 Xianlin Avenue, Nanjing 210023 China.

Acta biomaterialia

|February 22, 2026

概括

一种新型的双检查点纳米阻断剂 (dcMINB) 有效向CD73和PD-L1,增强T细胞透和抗瘤功效. 这种创新的免疫疗法策略实现了81%的瘤抑制率,为癌症治疗提供了一种有前途的新方法.

科学领域:

生物材料科学生物材料科学
免疫治疗是一种免疫疗法.
癌症生物学癌症生物学

背景情况:

免疫检查点阻塞 (ICB) 疗法在癌症治疗中表现有前途,但通常受到T细胞透率差和免疫抑制瘤微环境 (TME) 的限制.
现有策略面临的挑战是药物输送,TME复杂性和系统性毒性.

研究的目的:

开发一种新的双检查点分子印记纳米阻断器 (dcMINB),用于同时阻断CD73和PD-L1.
通过增强T细胞透和抗瘤功效,克服当前ICB疗法的局限性.

主要方法:

使用先进的分子印记技术设计的dcMINB创建了一种针对CD73和PD-L1.1的双特异人工抗体.
使用的聚乙烯甘醇 (PEG) 修改用于延长全身循环.
在体内静脉注射dcMINB以评估瘤积累和治疗效果.

主要成果:

dcMINB证明了优选的瘤积累,并有效地破坏了CD73介导的腺信号传递和PD-L1/PD-1轴.
通过dcMINB的双重抑制显著增强了T细胞透和激活.
实现了强大的抗瘤疗效,瘤抑制率为81%.

结论:

开发的dcMINB为双重免疫检查点提供了一个强有力的和可翻译的协同封锁策略.
这种方法有效地逆转瘤诱导的免疫抑制,并增强T细胞介导的抗瘤反应.
这项研究为基于ICB的协同治疗铺平了道路,改善了各种疾病的治疗窗口.

关键词:

免疫检查点是一个检查点.免疫疗法免疫疗法代谢检查点是代谢检查点.有分子印记的聚合物.瘤微环境是一个微环境.

更多相关视频

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...